SCHEMBL381655

SCHEMBL381655

CC(CN1CCN(c2ccc(Cl)cc2)CC1)C(=O)O.[LiH]

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.58
DRD4 P21917 4/20 0.52
DRD2 P14416 3/20 0.52
HTR1A P08908 3/20 0.51
GFER P55789 1/20 0.51
HTR7 P34969 2/20 0.51
ADRB2 P07550 1/20 0.51
ADRB1 P08588 1/20 0.51
ADRB3 P13945 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
OPRK1 P41145 1/20 0.48
LMNA P02545 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12041786 0.99 SMN1; SMN2 (0.59) SMN1; SMN2DRD4DRD2HTR1AGFER
Lithium Ion SCHEMBL9984414 0.84 SMN1; SMN2 (0.56) SMN1; SMN2DRD4DRD2HTR1AGFER
SCHEMBL381609 0.83 SMN1; SMN2 (0.59) SMN1; SMN2DRD4DRD2GFERHTR7
SCHEMBL4355715 0.83 MEN1 (0.62) HTR1AHTR7MAPTLMNAMEN1
SCHEMBL461854 0.83 MAPT (0.51) SMN1; SMN2DRD4GFERMAPTALDH1A1
SCHEMBL454734 0.82 PPARD (0.51) DRD4DRD2HTR1AALDH1A1
SCHEMBL12042014 0.82 MAPT (0.52) SMN1; SMN2DRD4GFERMAPTALDH1A1
SCHEMBL19107611 0.82 ALDH1A1 (0.60) DRD2HTR1AADRB2ADRB1ADRB3
SCHEMBL9984708 0.81 PPARD (0.52) DRD4DRD2HTR1AALDH1A1
SCHEMBL455662 0.81 PPARD (0.52) DRD4DRD2HTR1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
EP-2408742-B1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INT BV (NL) 2014-09-03 EP disclosed
EP-2408742-A1 ANTHELMINTIC AGENTS AND THEIR USE Intervet International B.V. (NL) 2012-01-25 EP disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
WO-2010115688-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO SMN1; SMN2 4633/4885DRD4 3926/4885DRD2 3527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.